Overview
As Director, Chris Lindsell, PhD leads the visionary strategic planning, development, and execution of state-of-the-art research for DCRI to achieve its scientific goals. He also serves as a member of the Senior Management Team and, along with Dr. Laine Thomas, will partner with Jack Shostak, Director of Statistical Operations, to execute research.
Lindsell has served as the Institute for Clinical and Translational Research Methods program Director, co-Director of the Center for Health Data Science, and professor of biostatistics and biomedical informatics at Vanderbilt University. He is a leader in the application of rigorous methods in the acute care environment, and to the intersection between emergency care and public health. He has led data coordinating centers for numerous multi-center clinical trials, including FDA-regulated trials, and epidemiological studies. His experience spans mechanistic studies, network trials, pragmatic trials, embedded trials, and more.
Lindsell holds patents for using clinical information, biomarkers and transcriptomics for prognosis and prediction in sepsis and septic shock with a goal of precision therapy in critical illness. He has contributed to data standards for CONNECTS, NHLBI’s network of networks for COVID-19 research, and to the DAQCORD guidelines for data collection and curation in observational studies. He has published over 350 peer-reviewed papers, and most recently, he has been leading multiple major data center efforts during the Covid-19 pandemic including TREAT NOW, ACTIV6 and the IVY Network.
Current Appointments & Affiliations
Recent Publications
Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM).
Journal Article J Clin Pharmacol · November 2025 Infliximab may play an important role in reducing mortality in severe COVID-19, though optimal dosing is unknown. This secondary analysis of the ACTIV-1 IM trial characterized infliximab pharmacokinetics and outcomes in patients hospitalized with severe CO ... Full text Link to item CiteEnabling inclusive systematic reviews: incorporating preprint articles with large language model-driven evaluations.
Journal Article J Am Med Inform Assoc · November 1, 2025 OBJECTIVES: Systematic reviews in comparative effectiveness research require timely evidence synthesis. With the rapid advancement of medical research, preprint articles play an increasingly important role in accelerating knowledge dissemination. However, ... Full text Link to item CiteProvider Behavioral Determinants and Preferences for Lung Cancer Screening Implementation: A Brief Report.
Journal Article JTO Clin Res Rep · November 2025 INTRODUCTION: Implementation of lung cancer screening is suboptimal. Understanding health care provider preferences and behavior is important for implementation. In this work, provider preferences for lung cancer screening implementation and self-reported ... Full text Link to item CiteRecent Grants
1/3 CTSA UM1 at Duke University
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2025 - 2032Liposomal Amphotericin B and Flucytosine Antifungal Strategies for Talaromycosis (LAmB-FAST) - R01
ResearchAdvisor · Awarded by National Institute of Allergy and Infectious Diseases · 2024 - 2031Combating Related Epidemics in HCV through Simplified Testing and Treatment (CREST). A cluster randomized trial of point-of-care hepatitis C testing and treatment among key populations
ResearchStatistical Investigator · Awarded by National Institutes of Health · 2025 - 2030View All Grants